Study of OP-3136 for advanced solid tumors
Treatments studied
Part of Cancer, Lungs & breathing, Skin clinical trials.
This trial tests a new drug, OP-3136, alone or with other drugs, for people with advanced breast cancer, prostate cancer, or lung cancer that has stopped responding to other treatments. It aims to see if OP-3136 is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or metastatic breast cancer that is ER+/HER2-, advanced prostate cancer (mCRPC), or non-small cell lung cancer (NSCLC).
- Your cancer has spread or cannot be removed with surgery.
- You have tried at least one prior treatment (like hormone therapy or a CDK4/6 inhibitor) and it stopped working.
- You have not had a previous treatment with a KAT6A/B inhibitor drug.
- Your cancer does not have active or untreated brain metastases that need treatment.
- You do not have serious heart problems or a stroke in the last 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests two experimental drugs, BNT323 and BNT327, together in people with advanced breast cancer. The goal is to find the best dose and see if the combination is safe and helpful.
This Phase 2 study tests a new Pfizer medicine (PF-07248144) for certain advanced or metastatic breast, prostate, or lung cancers that have not responded to standard treatment or no standard options exist. You may qualify if you have a specific tumor type and a limited number of prior cancer treatments, and if your body functions (blood, liver, kidneys) and heart rhythm meet safety limits.
This trial tests a new oral drug, MOMA-313, alone or with another drug (olaparib), in people whose cancer has a specific DNA repair problem (HR-deficient mutation). It aims to see if the drug can shrink tumors or slow their growth.
This trial tests a new study medicine (PF-07248144) combined with fulvestrant in people with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has worsened after previous treatments. It may be an option if you've already tried a CDK4/6 inhibitor and endocrine therapy.
This study tests a new medicine, PF-08032562, for people with advanced breast or colorectal cancer that has not responded to prior treatments. It aims to see if the drug is safe and can help shrink or slow the cancer.
This trial tests a new pill (M1774) combined with a hormone therapy called fulvestrant for people with advanced hormone-receptor-positive, HER2-negative breast cancer that has stopped responding to standard hormone therapy and CDK4/6 inhibitors. The study focuses on people with certain genetic markers in their tumor, hoping the combination will work better than current options.
Hear when a new Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.